Context Therapeutics
CNTX

$2.50

1.23%

Market Cap: 187M

About: Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Employees: 9

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 5 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

35% more capital invested

Capital invested by funds: $4.02M [Q4 2023] → $5.43M (+$1.41M) [Q1 2024]

9% more funds holding

Funds holding: 23 [Q4 2023] → 25 (+2) [Q1 2024]

2.36% more ownership

Funds ownership: 22.28% [Q4 2023] → 24.64% (+2.36%) [Q1 2024]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$4

60%

upside

Avg. target

$5.70

128%

upside

High target

$10

300%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Emily Bodnar	100%upside $5	Buy Reiterated	10 Jul 2024
Piper Sandler Joseph Catanzaro	80%upside $4.5	Overweight Initiated	16 May 2024
HC Wainwright & Co. Emily Bodnar	100%upside $5	Buy Maintained	9 May 2024
Maxim Group Jason McCarthy	300%upside $10	Buy Maintained	9 May 2024
HC Wainwright & Co. Emily Bodnar	60%upside $4	Buy Maintained	21 Mar 2024

See Analyst Rankings

Financial journalist opinion

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

Context Therapeutics Inc.'s acquisition of CT-95, targeting MSLN expressing solid tumors, brings another shot on goal for its pipeline of T cell engagers. CTIM-76 is another T cell engager in the pipeline; however, it is being developed to go after oncofetal protein CLDN6, which is only highly expressed in embryonic tissue. With both phase 1 studies of CT-95 and CTIM-76 underway soon, it is highly likely that preliminary data from both trials could be released in 2025.

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into an asset purchase agreement under which the Company has acquired CT-95, formerly owned by Link Immunotherapeutics, Inc. (“Link”), a mesothelin (“MSLN”) x CD3 T cell engaging (“TCE”) bispecific antibody with first-in-class potential that has received Investigational New Drug (“IND”) clearance from the U.S. Food and Drug Administration. CT-95 is on track for Phase 1 initiation in the first quarter of 2025.

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight

Hypergrowth stocks are the holy grail of traders and growth investors. These stocks can multiply a small position by two, five, 10 times, or more.

Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight

The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains

Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company.

The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains

Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice

Does Context Therapeutics Inc. (CNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice

Zacks Investment Research

Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why

Context Therapeutics Inc. (CNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and reported on recent business highlights. “We believe Context has had a great start to 2024 including achieving significant regulatory goals, demonstrating robust progress, and positioning us for future growth.

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for CTIM-76, a Claudin 6 (“CLDN6”) x CD3 T cell engaging bispecific antibody. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers.

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 Development Important Regulatory Milestone Supports Next Phase of CTIM-76 Development

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the year ended December 31, 2023, and reported on recent and upcoming business highlights. “During the fourth quarter of 2023, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 ("CLDN6”) x CD3 bispecific antibody, toward a first-in-human clinical study.

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

See News Rankings